To explore the prognostic efficacy and mechanism of ABCC5 clinical scoring model in hepatocellular carcinoma
This study constructed an ABCC5 clinical model and discovered that ABCC5 can serve as both a prognostic biomarker and therapeutic target for HCC. Multi-omics analysis and experimental validation confirmed that ABCC5 drives HCC progression by participating in immune microenvironment reprogramming, affecting cell cycle progression, and regulating the p53 signaling pathway. The research not only identified potential diagnostic markers and therapeutic targets, but the established prognostic model also provides new insights for investigating HCC pathogenesis and clinical translation.
Authors
- Chengyu Huang (ORCID: https://orcid.org/0000-0002-6473-8800)
- Ke Mo (ORCID: https://orcid.org/0009-0003-5910-6299)
- Miaoyun Long (ORCID: https://orcid.org/0000-0003-4231-6938)
- Zijun Li (ORCID: https://orcid.org/0000-0002-3029-5001)
- Yu Deng (ORCID: https://orcid.org/0000-0001-6065-512X)
- Ning Yang (ORCID: https://orcid.org/0000-0002-9158-4712)
- Junming Wu
Institutions
- Guangxi Academy of Agricultural Science (CN)
- Hai Kang Life (China) (CN)
- Guangdong Academy of Medical Sciences (CN)
- Guangxi Academy of Sciences (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-08-11
- DOI
- https://doi.org/10.3389/fonc.2025.1519533
- Primary Topic
- Drug Transport and Resistance Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00